Averion International, the US-based contract research organisation that strengthened its European offering last July by opening an office in Ukraine, has now moved into the Czech Republic.

The latest office, in the Czech capital Prague, is headed by Dr Libor Hubacek as country manager for Averion in the Czech Republic. He brings to the CRO 10 years’ experience in the monitoring, submission and management of clinical trials in that country, with special expertise in arterial hypertension, oncology, renal impairment, pulmonology, urinary tract infection, atherosclerosis, diabetes mellitus, cystic fibrosis and other therapeutic areas.

“Averion continues to expand its European footprint to meet the needs of our clients,” commented chief executive officer Dr Markus Weissbach. “In the heart of Central Eastern Europe, the Czech Republic offers a strong clinical trial environment with large patient populations and well-qualified investigators in a broad range of indications. These critical factors are top priorities for our clients and they are vital to the successful conduct of international trials.”

The new office is staffed by experienced Clinical Research Associates and Clinical Trial Assistants, with additional hirings expected in the coming months, Averion noted.

As well as its recently opened office in Kiev, Ukraine, the CRO has Central and Eastern European offices in Poland and Russia as well as operations centres in Slovakia and Hungary. Overall, Averion’s international network extends from the US to Switzerland, France, the Netherlands, the UK, Poland, Russia, the Czech Republic, Slovakia, Hungary, Ukraine, Germany, Austria and Israel. The CRO also has research partnerships in India, Asia and South America.

Formed in August 2006 from the merger of Averion Inc, IT&E International and Millennix Inc, Averion International provides services ranging from product registration support to site selection, monitoring, data management, pharmacovigilance and full clinical trial management, with a particular focus on oncology, cardiovascular diseases and medical devices.